Hookipa Pharma's Cancer Immunotherapy Shows T-Cell Response, Interim Efficacy in Pretreated HPV16+ Cancer SettingsBenzinga • 06/08/21
HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancersGlobeNewsWire • 06/07/21
HOOKIPA Pharma Inc. (HOOK) Soars 7.9%: Is Further Upside Left in the Stock?Zacks Investment Research • 05/19/21
HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/12/21
HOOKIPA Pharma Reports First Quarter 2021 Financial Results and Recent HighlightsGlobeNewsWire • 05/12/21
HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancersGlobeNewsWire • 04/10/21
HOOKIPA Pharma Inc. (HOOK) CEO Joern Aldag on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/18/21
HOOKIPA Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 OutlookGlobeNewsWire • 03/18/21
Hookipa: Data Readouts Of 2021's HB-101, HB-201, And HB-201/-202 Hold Promising UpsideSeeking Alpha • 12/31/20
HOOKIPA Pharma Announces Closing of Public Offering of $80.9 Million of Common Stock and Preferred Stock, Including Full Exercise of Underwriters' OptionGlobeNewsWire • 12/11/20
HOOKIPA Pharma Announces Pricing of Public Offering of Common Stock and Preferred StockGlobeNewsWire • 12/09/20
HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Preferred StockGlobeNewsWire • 12/08/20
HOOKIPA Interim Phase 1 Monotherapy Data of HB-201 for the Treatment of Advanced HPV16+ Cancers Shows Promising Anti-Tumor Activity and Favorable TolerabilityGlobeNewsWire • 12/07/20
HOOKIPA Announces Positive Phase 2 Interim Safety, Immunogenicity, and Efficacy Data for its Cytomegalovirus Vaccine Candidate HB-101GlobeNewsWire • 11/30/20
HOOKIPA Pharma Reports Third Quarter 2020 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 11/12/20
HOOKIPA Pharma To Report Third Quarter 2020 Financial Results on November 12, 2020GlobeNewsWire • 11/03/20
HOOKIPA Pharma’s LCMV-based Immunotherapy for HPV16+ Cancers Demonstrates High Immunogenicity, According to Peer Reviewed ArticleGlobeNewsWire • 09/16/20